EP2149606B1 - Molécules d'acide nucléique et procédés pour identifier les modulateurs de l'activité GPR84 - Google Patents

Molécules d'acide nucléique et procédés pour identifier les modulateurs de l'activité GPR84 Download PDF

Info

Publication number
EP2149606B1
EP2149606B1 EP09166858.2A EP09166858A EP2149606B1 EP 2149606 B1 EP2149606 B1 EP 2149606B1 EP 09166858 A EP09166858 A EP 09166858A EP 2149606 B1 EP2149606 B1 EP 2149606B1
Authority
EP
European Patent Office
Prior art keywords
gpr84
nucleic acid
sequences
proteins
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP09166858.2A
Other languages
German (de)
English (en)
Other versions
EP2149606A1 (fr
Inventor
Stephen Anthony Gravina
Jason M. Montez
Hailin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Flavors and Fragrances Inc
Original Assignee
International Flavors and Fragrances Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Flavors and Fragrances Inc filed Critical International Flavors and Fragrances Inc
Publication of EP2149606A1 publication Critical patent/EP2149606A1/fr
Application granted granted Critical
Publication of EP2149606B1 publication Critical patent/EP2149606B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • Taste signaling is found throughout the animal kingdom, from simple metazoans to the most complex of vertebrates. Taste sensation is believed to be mediated by receptors, i . e ., metabotropic or inotropic receptors. Cells which express taste receptors, when exposed to certain chemical stimuli, elicit taste sensation by depolarizing to generate an action potential, which triggers the sensation. As such, taste receptors specifically recognize molecules that elicit specific taste sensation. These molecules are also referred to herein as "tastants.” Many taste receptors belong to the 7-transmembrane receptor superfamily ( Hoon, et al. (1999) Cell96:451 ; Adler, et al. (2000) Cell100:693 ), which are also known as G protein-coupled receptors (GPCRs). Other tastes are believed to be mediated by channel proteins.
  • GPCRs G protein-coupled receptors
  • G ⁇ complex When a G ⁇ complex operatively associates with an activated G protein-coupled receptor in a cell membrane, the rate of exchange of GTP for bound GDP is increased and the rate of dissociation of the bound G ⁇ subunit from the G ⁇ complex increases.
  • the free G ⁇ subunit and G ⁇ complex are thus capable of transmitting a signal to downstream elements of a variety of signal transduction pathways. These events form the basis for a multiplicity of different cell signaling phenomena, including for example the signaling phenomena that are identified as neurological sensory perceptions such as taste and/or smell.
  • Mammals are believed to have five basic taste modalities, sweet, bitter, sour, salty, and umami (the taste of monosodium glutamate). See, e . g ., Kinnamon, et al. (1992) Ann. Rev. Physiol. 54:715-31 ; Lindemann (1996) Physiol. Rev. 76:718-66 ; Stewart, et al. (1997) Am. J Physiol. 272:1-26 . Numerous physiological studies in animals have shown that taste receptor cells may selectively respond to different chemical stimuli. See, e.g., Akabas, et al. (1988) Science 242:1047-50 ; Gilbertson, et al. (1992) J. Gen. Physiol. 100:803-24 ; Bernhardt, et al. (1996) J. Physiol. 490:325-36 ; Cummings, et al. (1996) J. Neurophysiol. 75:1256-63 .
  • Matsumara et al. (2007. Biomedical Research, 28, pp.49-55 ) describes GPR expression in the rat taste bud relating to fatty acid sensing.
  • an isolated nucleic acid molecule encoding CD36, G qi9 , and G protein-coupled receptor 84 (GPCR84) proteins.
  • GPCR84 G protein-coupled receptor 84
  • Expression vectors with inducible or constitutive expression of CD36, G qi9 , and GPR84 are also embraced by the present invention.
  • an isolated recombinant host cell transformed with an expression vector of the invention and which co-expresses CD36, G qi9 , and GPR84 proteins.
  • the method involves contacting a recombinant host cell, which co-expresses CD36, G qi9 , and GPCR84 proteins, with a test compound and determining the functional effect of the test compound on GPR84 activity thereby identifying a modulator of GPR84
  • GPR84 G protein-coupled receptor 84
  • CD36 CD36
  • G qi 9 G protein-coupled receptor 84
  • GPR84 can be a fat taste receptor and may be used in screening assays for compounds that mimic fat taste.
  • nucleic acid molecules described herein may be isolated or otherwise associated with structures or compounds to which they are not normally associated in nature, according to a variety of methods and processed known to those of skill in the art.
  • GPR84 has been identified as a receptor for medium-chain free fatty acids (Wang, et al. (2006) supra).
  • the GPR84 protein is found in a variety of species including human, mouse, rat, and the like and nucleic molecules encoding any one of these proteins can be used in accordance with the present invention.
  • the present invention embraces nucleic acid molecules encoding GPR84 proteins listed in Table 1. TABLE 1 Source GENBANK Accession No. of Amino Acid Sequence SEQ ID NO: GENBANK Accession No.
  • the nucleic acid molecule encodes a human GPR84 protein. In other embodiments, the nucleic acid molecule encodes a human GPR84 protein of SEQ ID NO:1. In particular embodiments, the nucleic acid molecule encoding human GRP84 protein is set forth in SEQ ID NO:9.
  • the GPR84 proteins disclosed herein are members of a family of related seven transmembrane G protein-coupled receptors, which are believed to be involved in taste transduction.
  • the nucleotide sequences of the GPR84 family members can encode related proteins including an extracellular domain, seven transmembrane domains, and a cytoplasmic domain.
  • Related GPR84 family members from other species share at least about 60%, 70%, 80%, or 90% protein sequence identity over a region of at least about 50 amino acid residues in length, optionally 100, 200, 300, or more amino acid residues in length to SEQ ID NOs: 1, 3, 5 or 7.
  • Specific regions of the GPR84 amino acid sequences can be used to identify polymorphic variants, interspecies homologs, and alleles of GPR84 family members. This identification can be made in vitro, e . g ., under stringent hybridization conditions or PCR ( e . g ., using primers encoding GPR84 consensus sequences), or by using the sequence information in a computer system for comparison with other nucleotide sequences. Different alleles of GPR84 genes within a single species population will also be useful in determining whether differences in allelic sequences correlate to differences in taste perception between members of the population.
  • Classical PCR-type amplification and cloning techniques are useful for isolating orthologs, for example, where degenerate primers are sufficient for detecting related genes across species, which typically have a higher level of relative identity than paralogous members of the GPR84 family within a single species.
  • identification of polymorphic variants and alleles of GPR84 family members can be made by comparing an amino acid sequence of about 25 amino acids or more, e . g ., 50-100 amino acids. Amino acid identity of approximately at least 60%, 70%, 75%, 80%, 85%, 90%, 95-99%, or above typically demonstrates that a protein is a polymorphic variant, interspecies homolog, or allele of a T1R family member. Sequence comparison can be performed using any conventional sequence comparison algorithms. Antibodies that bind specifically to GPR84 polypeptides or a conserved region thereof can also be used to identify alleles, interspecies homologs, and polymorphic variants.
  • the nucleic acid molecule of the invention further encodes a chimeric guanine nucleotide-binding protein (G protein) composed of the G protein ⁇ q subunit, wherein the C-terminal nine residues have been replaced by those of the G protein ⁇ i subunit.
  • G protein chimeric guanine nucleotide-binding protein
  • This chimeric G protein termed G qi9 , is known in the art and described by Parmentier, et al. (1998) Mol. Pharmacol.53(4):778-86 ; Perroy, et al. ((2001) J. Biol. Chem.276: 45800-45805 ) for coupling receptors to phospholipase C.
  • the nine C-terminal amino acid residues of the Gq subunit set forth in GENBANK Accession No. NP_002063.2 are replaced with the nine C-terminal amino acid residues of the G protein ⁇ i subunit, i . e ., Asn-Asn-Leu-Lys-Asp-Cys-Gly-Leu-Phe (SEQ ID NO:11).
  • the human Gq subunit is desirably employed in the present invention, non-human Gq subunit can also be used.
  • the Gq subunits listed in Table 2 would be suitable for use in the present invention. TABLE 2 Source GENBANK Accession No.
  • G q subunits of use in accordance with the present invention desirably share at least about 90% protein sequence identity over a region of at least about 50 amino acid residues in length, optionally 100, 200, 300, or more amino acid residues in length to SEQ ID NOs: 10, 13, or 15.
  • related sequences can be identified using a variety of conventional methods, using stringent hybridization conditions or antibody cross-reactivity.
  • CD36 Further included in the nucleic acid molecule of the present invention are sequences encoding CD36. It has been suggested that GPR120 and CD36 form an independent pathway for fatty acid reception ( Matsumura, et al. (2007) Biomed. Res. 28:49-55 ). Moreover, it is contemplated that CD36 also functions in conjunction with GPR84 in fatty acid transport and sensing of dietary lipids. Thus, the present invention embraces the co-expression of CD36 with GPR84 and G qi9 . While the human CD36 is desirably employed in the present invention, non-human CD36 can also be used. For example, the CD36 proteins listed in Table 3 would be suitable for use in the present invention. TABLE 3 Source GENBANK Accession No.
  • CD36 proteins disclosed herein function as fatty acid transporters
  • the present invention embraces other CD36 proteins sharing at least about 90% protein sequence identity over a region of at least about 50 amino acid residues in length, optionally 100, 200, 300, or more amino acid residues in length to SEQ ID NOs: 17, 19, or 21.
  • amino acid sequences of the proteins of the invention can be identified by putative translation of the coding nucleic acid sequences. These various amino acid sequences and the coding nucleic acid sequences can be compared to one another or to other sequences according to a number of methods.
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, as described below for the BLASTN and BLASTP programs, or alternative parameters can be designated.
  • sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
  • a “comparison window,” as used herein, includes reference to a segment of any one of the number of contiguous positions, e . g ., from 20 to 600, usually about 50 to about 200 or about 100 to about 150 in which a sequence can be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
  • Methods of alignment of sequences for comparison are well-known in the art.
  • Optimal alignment of sequences for comparison can be conducted, e . g ., by the local homology algorithm of Smith & Waterman ((1981) Adv. Appl. Math. 2:482 ), by the homology alignment algorithm of Needleman & Wunsch ((1970) J. Mol. Biol.
  • a preferred example of an algorithm that is suitable for determining percent sequence identity are the BLAST and BLAST 2.0 algorithms, which are described by Latched, et al. (1977) Nuc. Acids Res. 25:3389-3402 , and Altschul, et al. (1990) J. Mol Biol. 2 15:403-410 , respectively.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul, et al.
  • Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a so-called “tree” or “dendogram” showing the clustering relationships used to create the alignment.
  • PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle ((1987) J. Mol. Evol. 35:351-360 ). The method used is similar to the method described by Higgins & Sharp ((1989) CABIOS 5:151-153 ). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids.
  • the multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments.
  • the program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters.
  • PILEUP a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.
  • PILEUP can be obtained from the GCG sequence analysis software package ( Devereaux, et al. (1984) Nuc. Acids Res. 12:387-395 ).
  • suitable GPR84, Gq subunit and CD36 proteins can be identified by hybridization of nucleic acid molecules (e . g ., the nucleic acid molecules disclosed in Tables 1-3, or probes thereof) under stringent hybridization conditions to nucleic acids from other species (e . g ., genomic or cDNA sequences).
  • nucleic acid molecules e . g ., the nucleic acid molecules disclosed in Tables 1-3, or probes thereof
  • stringent hybridization conditions refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures.
  • T m thermal melting point
  • Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes ( e . g ., 10 to 50 nucleotides) and at least about 60°C for long probes ( e . g ., greater than 50 nucleotides).
  • Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide.
  • a positive signal is at least two times background, optionally 10 times background hybridization.
  • Exemplary stringent hybridization conditions can be as follows: 50% formamide, 5X SSC, and 1% SDS with incubation at 42°C (or 5X SSC, 1% SDS with incubation at 65°C) with a wash in 0.2X SSC and 0.1% SDS at 65°C.
  • Such hybridizations and wash steps can be carried out for, e . g ., 1, 2, 5, 10, 15, 30, 60, or more minutes.
  • Nucleic acids that do not hybridize to each other under stringent conditions are still substantially related if the polypeptides which they encode are substantially related. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions.
  • Exemplary "moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. Such hybridizations and wash steps can be carried out for, e . g ., 1, 2, 5, 10, 15, 30, 60, or more minutes. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.
  • nucleic acid molecules encoding the GPR84, Gq subunit and CD36 proteins of the invention can be isolated from a variety of sources, genetically engineered, amplified, synthesized, and/or expressed recombinantly according to methods well-known in the art. Isolation and expression of the proteins of the present invention can be performed as described below. PCR primers can be used for the amplification of nucleic acids encoding GPR84, Gq subunit and CD36 proteins, and libraries of these nucleic acids can optionally be generated and screened for the identification of a suitable nucleic acid molecule for protein expression.
  • Amplification methods are well-known in the art, and include, e.g., polymerase chain reaction, PCR (PCR Protocols, a Guide to Methods and Applications (1990) ed. Innis. Academic Press, NY , and PCR Strategies (1995) ed. Innis, Academic Press, Inc., NY ); ligase chain reaction (LCR) (see, e . g ., Wu (1989) Genomics 4:560 ; Landegren (1988) Science 241:1077 ; Barringer (1990) Gene 89:117 ); transcription amplification (see, e . g ., Kwoh (1989) Proc. Natl. Acad. Sci.
  • LCR ligase chain reaction
  • the primers can encode amino acid residues that are conservative substitutions (e . g ., hydrophobic for hydrophobic residue or functionally benign substitutions ( e . g ., do not prevent plasma membrane insertion, cause cleavage by peptidase, cause abnormal folding of receptor, and the like).
  • the nucleic acids either individually or as libraries, can be cloned according to methods known in the art. Indeed, techniques for the manipulation of nucleic acids, such as, for example, for generating mutations in sequences, subcloning, labeling probes, sequencing, hybridization and the like are well-described in the scientific and Patent literature. See, e.g., Sambrook, ed.
  • nucleic acids of the invention can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Carruthers (1982) Cold Spring Harbor Symp. Quant. Biol. 47:411-418 ; Adams (1983) Am. Chem. Soc. 105:661 ; Belousov (1997) Nucleic Acids Res. 25:3440-3444 ; Frenkel (1995) Free Radic. Biol. Med. 19:373-380 ; Blommers (1994) Biochemistry 33:7886-7896 ; Narang (1979) Meth. Enzymol. 68:90 ; Brown (1979) Meth. Enzymol. 68:109 . Double-stranded DNA fragments can then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.
  • nucleic acids encoding the GPR84, Gq subunit and CD36 proteins are introduced into an expression vector for recombinant protein expression.
  • any expression vector system can be used, including, in addition to mammalian cells, e . g ., bacterial, yeast, insect, or plant systems.
  • expression vector refers to any recombinant expression system for the purpose of expressing a nucleic acid molecule of the invention, constitutively or inducibly, in any cell, including prokaryotic, yeast, fungal, plant, insect or mammalian cell. The term includes linear or circular expression systems.
  • the term includes expression systems that remain episomal or integrate into the host cell genome.
  • the expression systems can have the ability to self-replicate or not, i . e ., drive only transient expression in a cell.
  • the term includes recombinant expression cassettes which contain only the minimum elements needed for transcription of the recombinant nucleic acid.
  • nucleic acids of the invention are operably linked to transcriptional or translational control elements, e . g ., transcription and translation initiation sequences, promoters and enhancers, transcription and translation terminators, polyadenylation sequences, and other sequences useful for transcribing DNA into RNA.
  • a promoter can be operably-linked to one or more nucleic acid molecules of the invention to direct expression of the desired nucleic acid in all or a subset of cells or tissues.
  • a "promoter” is defined as an array of nucleic acids that direct transcription of a nucleic acid.
  • a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element.
  • a promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.
  • constitutive or inducible promoters are employed.
  • a "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. Examples of constitutive promoters include, but are not limited to, the P-actin promoter and the CMV promoter.
  • An “inducible” promoter is a promoter that is active under environmental or developmental regulation.
  • inducible promoters include, but are not limited to, the human c-fos promoter, steroid-inducible promoters such as a glucocorticoid-inducible promoter, and small molecule inducible promoters such as the tetracycline regulated promoter.
  • Promoters of the invention are The term "operably-linked” refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid molecule, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
  • the nucleic acid molecules encoding GPR84, CD36 and G qi9 are introduced, in tandem, into one expression vector for expression as individual proteins in a host cell.
  • the nucleic acid molecules encoding GPR84, CD36 and G qi9 are each introduced into different expression vectors for co-expression in a host cell.
  • two expression vectors are employed with various combinations of nucleic acid molecules encoding GPR84, CD36 and G qi9 ( e . g ., one expression vector harbors GPR84 and G qi9 nucleic acids and the other expression vector harbors CD36 nucleic acids).
  • the proteins of the present invention can be expressed as fusion proteins, e . g ., a GPR84-G qi9 fusion protein.
  • nucleic acid molecules encoding GPR84, CD36 and G qi9 are introduced, in tandem, into one expression vector for co-expression of individual proteins in a host cell, some embodiments embrace the use of one promoter for regulating the expression of all three proteins.
  • the nucleic acid molecules encoding GPR84, CD36 and G qi9 are separated from each other by Internal Ribosome Entry Sites (IRESs). IRES elements are known from viral and mammalian genes ( Martinez-Salas (1999) Curr. Opin. Biotechnol.
  • IRES is an element encoded in DNA that results in a structure in the transcribed RNA at which eukaryotic ribosomes can bind and initiate translation.
  • An IRES permits two or more proteins to be produced from a single RNA molecule (the first protein is translated by ribosomes that bind the RNA at the cap structure of its 5' terminus, (Martinez-Salas (1999) supra).
  • nucleic acid molecules encoding GPR84, CD36 and G qi9 into one expression vector, wherein the coding sequence for each protein has its own regulatory sequences.
  • specific embodiments of the invention include a nucleic acid molecule containing, in order, the following sequences: promoter 1 -> CD36 coding sequence -> polyA signal -> promoter 2 -> G qi9 coding sequence -> polyA signal -> promoter 3 -> GPR84 coding sequence -> polyA signal, wherein promoter 1-3 can be the same or different, or inducible or constitutive.
  • Expression vectors either as individual expression vectors for co-expressing GPR84, CD36 or G qi9 proteins, or one expression vector harboring nucleic acids encoding GPR84, CD36 and G qi9 proteins can be introduced into a genome or into the cytoplasm or a nucleus of a host cell and expressed by a variety of conventional techniques well-described in the scientific and Patent literature. See, e . g ., Roberts, (1987) Nature 328:731 ; and Sambrook, ed. (1989) supra ). Product information from manufacturers of biological reagents and experimental equipment also provide information regarding known biological methods.
  • the vectors can be isolated from natural sources, obtained from such sources as ATCC or GENBANK libraries, or prepared by synthetic or recombinant methods.
  • the nucleic acids of the invention can be expressed in expression cassettes or vectors (including plasmids and viruses) which are stably or transiently maintained in cells (e.g., episomal expression systems).
  • Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences.
  • selection markers can code for episomal maintenance and replication such that integration into the host genome is not required.
  • the marker may encode antibiotic resistance (e . g ., chloramphenicol, kanamycin, G418, bleomycin, hygromycin) or herbicide resistance ( e .g., chlorosulfuron) to permit selection of those cells transformed with the desired DNA sequences (see, e . g ., Blondelet-Rouault (1997) Gene 190:315-317 ; Aubrecht (1997) J. Pharmacol. Exp. Ther. 281:992-997 ).
  • antibiotic resistance e . g ., chloram
  • host cell is meant a cell that contains an expression vector and supports the replication or expression of the expression vector.
  • Host cells can be prokaryotic cells such as E.
  • coli or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, HEK-293, and the like, e.g., cultured cells, explants, and cells in vivo.
  • mammalian cells such as CHO, HeLa, HEK-293, and the like, e.g., cultured cells, explants, and cells in vivo.
  • the host cell can be mammalian or non-mammalian, with preference given to mammalian host cells.
  • Any of the well-known procedures for introducing the expression vector(s) of the invention into host cells can be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well-known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al. supra) After the expression vector is introduced into the host cells, the transfected cells are cultured under conditions favoring expression of the proteins of the invention.
  • Host cells of the invention which co-express GPR84, CD36 or G qi9 proteins from one or more expression vectors find application in analyzing fatty acid transport and sensing of dietary lipids as well as in methods for identifying agents which modulate GPR84 activity.
  • modulators e.g ., activators, inhibitors, stimulators, enhancers, agonists, and antagonists
  • Such modulators of GPR84 activity are useful for pharmacological, chemical, and genetic modulation of taste signaling pathways.
  • These methods of screening can be used to identify high affinity agonists and antagonists of taste cell activity.
  • modulatory compounds can then be used in the food and pharmaceutical industries to customize taste, e . g ., to modulate the tastes of foods.
  • Inhibitors are compounds that, e . g ., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate GPR84 activity, e . g ., antagonists.
  • Activators are compounds that, e.g., bind to, stimulate, increase, open, activate, facilitate, enhance activation, sensitize, or up regulate GPR84 activity, e . g ., agonists.
  • Modulators also include compounds that, e.g., alter the interaction of a receptor with extracellular proteins that bind activators or inhibitors, G proteins, or kinases.
  • Such assays for inhibitors and activators include, e . g ., expressing GPR84, CD36 and G qi9 in cells or cell membranes, applying putative modulator compounds and then determining the functional effects on taste transduction. Results of assays with potential activators, inhibitors, or modulators are compared to control samples without the inhibitor, activator, or modulator to examine the extent of modulation of GPR84 activity. Control samples (untreated with modulators) are assigned a relative GPR84 activity value of 100%.
  • Inhibition of a GPR84 is achieved when the GPR84 activity value relative to the control is about 80%, optionally 50% or 25-0%.
  • Activation of a GPR84 is achieved when the GPR84 activity value relative to the control is 110%, optionally 150%, optionally 200-500%, or 1000-3000% higher.
  • Assays can be provided for detecting and characterizing taste modulation, wherein GPR84 is used as a reporter molecule for determining the functional effect of modulators on fatty acid taste transduction.
  • the phrase "functional effect(s)" in the context of assays for testing compounds that modulate GPR84 activity includes the determination of any parameter that is indirectly or directly under the influence of the receptor, e.g., functional, physical and chemical effects. It includes ligand binding, changes in ion flux, membrane potential, current flow, transcription, G protein binding, GPCR phosphorylation or dephosphorylation, signal transduction, receptor-ligand interactions, second messenger concentrations (e.g., cAMP, cGMP, IP 3 , or intracellular Ca 2+ ).
  • determining the functional effect in the context of assays herein is meant assays for a compound that increases or decreases a parameter that is indirectly or directly under the influence of GPR84, e.g., functional, physical and chemical effects.
  • Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties; patch clamping; voltage-sensitive dyes; whole cell currents; radioisotope efflux; inducible markers; ligand-binding assays; voltage, membrane potential and conductance changes; ion flux assays; changes in intracellular second messengers such as cAMP, cGMP, and inositol triphosphate (IP 3 ); changes in intracellular calcium levels; and the like.
  • spectroscopic characteristics e.g., fluorescence, absorbance, refractive index
  • hydrodynamic
  • Taste receptors bind tastants and initiate the transduction of chemical stimuli into electrical signals.
  • An activated or inhibited G protein will in turn alter the properties of target enzymes, channels, and other effector proteins.
  • Some examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G protein, phospholipase C by G q and other cognate G proteins, and modulation of diverse channels by G i and other G proteins.
  • Downstream consequences can also be examined such as generation of diacyl glycerol and IP 3 by phospholipase C, and in turn, for calcium mobilization by IP 3 . Accordingly, activation of GPR84 can be detected using monitoring changes in intracellular calcium by detecting FURA-2-dependent fluorescence in the host cell.
  • Activated GPCR receptors become substrates for kinases that phosphorylate the C-terminal tail of the receptor (and possibly other sites as well).
  • activators can promote the transfer of 32 P from gammalabeled GTP to the receptor, which can be assayed with a scintillation counter.
  • the phosphorylation of the C-terminal tail will promote the binding of arrestin-like proteins and will interfere with the binding of G proteins.
  • the kinase/arrestin pathway plays a key role in the desensitization of many GPCR receptors. For example, compounds that modulate the duration a taste receptor stays active would be useful as a means of prolonging a desired taste or cutting off an unpleasant one.
  • ion flux assays can be carried out to determine whether a compound modulated GPR84 activity. Changes in ion flux can be assessed by determining changes in ionic polarization (i . e ., electrical potential) of the cell or membrane expressing a GPR84 protein. One means to determine changes in cellular polarization is by measuring changes in current (thereby measuring changes in polarization) with voltage-clamp and patch-clamp techniques (see e . g ., Ackerman, et al. (1997) New Engl. J Med. 336:1575-1595 ). Whole cell currents are conveniently determined using a standard.
  • the effects of the test compounds upon the function of GPR84 can be measured by examining any of the parameters described above. Any suitable physiological change that affects GPCR activity can be used to assess the influence of a test compound on GPR84.
  • any suitable physiological change that affects GPCR activity can be used to assess the influence of a test compound on GPR84.
  • the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e . g ., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as Ca 2+ , IP 3 , cGMP, or cAMP.
  • Preferred assays for GPCRs include cells that are loaded with ion or voltage sensitive dyes to report receptor activity. Assays for determining activity of such receptors can also use known agonists and antagonists for other G protein-coupled receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (e . g ., agonists, antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that can be employed are those disclosed in the Molecular Probes 1997 Catalog.
  • cyclic nucleotide-gated ion channels e . g ., rod photoreceptor cell channels and olfactory neuron channels that are permeable to cations upon activation by binding of cAMP or cGMP (see, e . g ., Altenhofen, et al. (1991) Proc. Natl Acad. Sci.
  • cyclic nucleotide levels it may be preferable to expose the cells to agents that increase intracellular cyclic nucleotide levels, e . g ., forskolin, prior to adding a receptor-activating compound to the cells in the assay.
  • agents that increase intracellular cyclic nucleotide levels e . g ., forskolin
  • Cells for this type of assay can be made by co-transfection of a host cell with DNA encoding a cyclic nucleotide-crated ion channel, GPCR phosphatase and DNA encoding a receptor ( e .
  • the uptake of fluorescently labeled fatty acids via CD36 can be used as an indication of activity.
  • Such an assay is commercially available from sources such as Molecular Devices (Sunnyvale, CA) for use with FLIPR.
  • Non-human animals expressing GPR84 can also be used for receptor assays. Such expression can be used to determine whether a test compound specifically binds to a mammalian taste transmembrane receptor polypeptide in vivo by contacting a non-human animal stably or transiently transfected with a nucleic acid molecule of the invention with a test compound and determining whether the animal reacts to the test compound by specifically binding to the receptor polypeptide.
  • Animals transfected or infected with the vectors of the invention are particularly useful for assays to identify and characterize tastants/ligands that can bind to a specific or sets of receptors.
  • Such vector-infected animals expressing human chemosensory receptor sequences can be used for in vivo screening of tastants and their effect on, e.g., cell physiology (e.g., on taste neurons), on the CNS, or behavior.
  • nucleic acid molecules of the invention can be for example expressed in animal taste tissues by delivery with an infecting agent, e.g., adenovirus expression vector.
  • the compounds tested as modulators of GPR84 can be any small chemical compound, or a biological entity, such as a protein, nucleic acid or lipid.
  • test compounds will be small chemical molecules and peptides.
  • any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used.
  • the assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel ( e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland) and the like.
  • High throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such libraries are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity.
  • the compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.
  • GPR84 modulators identified can be used in any food product, confectionery, pharmaceutical composition, or ingredient thereof to thereby modulate the taste of the product, composition, or ingredient in a desired manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Claims (5)

  1. Une molécule d'acide nucléique isolée codant les protéines CD36, Gqi9, et du récepteur couplé à la protéine G 84 (GPR84).
  2. Un vecteur d'expression contenant la molécule d'acide nucléique selon la Revendication 1.
  3. Le vecteur d'expression selon la Revendication 2, où l'expression de CD36, Gqi9 et GPR84 est inductible.
  4. Le vecteur d'expression selon la Revendication 2, où l'expression de CD36, Gqi9 et GPR84 est constitutive.
  5. Une cellule hôte isolée transformée avec le vecteur d'expression selon la Revendication 2 et qui co-exprime les protéines CD36, Gqi9 et GPR84.
EP09166858.2A 2008-08-01 2009-07-30 Molécules d'acide nucléique et procédés pour identifier les modulateurs de l'activité GPR84 Not-in-force EP2149606B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/184,368 US7674891B2 (en) 2008-08-01 2008-08-01 Nucleic acid molecules encoding GPR84

Publications (2)

Publication Number Publication Date
EP2149606A1 EP2149606A1 (fr) 2010-02-03
EP2149606B1 true EP2149606B1 (fr) 2015-07-22

Family

ID=41059618

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09166858.2A Not-in-force EP2149606B1 (fr) 2008-08-01 2009-07-30 Molécules d'acide nucléique et procédés pour identifier les modulateurs de l'activité GPR84

Country Status (4)

Country Link
US (1) US7674891B2 (fr)
EP (1) EP2149606B1 (fr)
CN (1) CN101654676A (fr)
ES (1) ES2545485T3 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7900425B2 (en) 2005-10-14 2011-03-08 Graham Packaging Company, L.P. Method for handling a hot-filled container having a moveable portion to reduce a portion of a vacuum created therein
GB201122146D0 (en) * 2011-12-22 2012-02-01 Galapagos Nv Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509702A (ja) 1991-04-05 1994-11-02 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 匂い物質受容体およびその使用
IL108205A0 (en) 1993-12-28 1994-04-12 Yeda Res & Dev Olfactory genes and receptors
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
WO1997017444A2 (fr) 1995-11-09 1997-05-15 Johns Hopkins University School Of Medicine Nouveaux recepteurs du sperme
US5874243A (en) 1997-03-28 1999-02-23 Smithkline Beecham Corporation OLRCC15 receptor
US6316693B1 (en) * 1997-10-02 2001-11-13 The Research Foundation Of The State University Of New York Transgenic mouse model for fatty acid transport
FR2780405B1 (fr) 1998-06-25 2001-12-28 Centre Nat Rech Scient Nouveaux recepteurs olfactifs et leurs utilisations
EP1929310A2 (fr) 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Utilisation du recepteur humain couple aux proteines g et de ses modulateurs pour le traitement de l'atherosclerose et de troubles atherosclerotiques, et d'etats lies a l'expression du mcp-1
US7781209B2 (en) * 2005-09-25 2010-08-24 Multispan, Inc. GPCR-expressing cell lines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG J ET AL: "Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 281, no. 45, 11 September 2006 (2006-09-11), pages 34457 - 34464, XP002546609, ISSN: 0021-9258, DOI: 10.1074/JBC.M608019200 *

Also Published As

Publication number Publication date
ES2545485T3 (es) 2015-09-11
US20100028929A1 (en) 2010-02-04
CN101654676A (zh) 2010-02-24
US7674891B2 (en) 2010-03-09
EP2149606A1 (fr) 2010-02-03

Similar Documents

Publication Publication Date Title
US10093718B2 (en) T1R taste receptors and genes encoding same
CA2433514C (fr) Recepteurs du gout t1r et genes les codant
US7105650B2 (en) T2R taste receptors and genes encoding same
US20030157568A1 (en) SF, a novel family of taste receptors
AU2001240086A1 (en) T1r taste receptors and genes encoding same
EP2149606B1 (fr) Molécules d'acide nucléique et procédés pour identifier les modulateurs de l'activité GPR84
WO2001098526A2 (fr) Cartographie de recepteurs, perception sensorielle et biocapteurs d'agents sensoriels chimiques
WO2003027142A1 (fr) Nouveau recepteur couple a la proteine g

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

17P Request for examination filed

Effective date: 20100322

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MONTEZ, JASON M.

Inventor name: GRAVINA, STEPHEN ANTHONY

Inventor name: WANG, HAILIN

17Q First examination report despatched

Effective date: 20100520

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/12 20060101AFI20141009BHEP

Ipc: C12N 15/63 20060101ALI20141009BHEP

Ipc: C07K 14/705 20060101ALI20141009BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150105

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 737949

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150815

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009032308

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2545485

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150911

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 737949

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150722

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151023

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151022

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20151030

Year of fee payment: 7

Ref country code: GB

Payment date: 20151027

Year of fee payment: 7

Ref country code: DE

Payment date: 20151102

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151122

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20151113

Year of fee payment: 7

Ref country code: FR

Payment date: 20151027

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009032308

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

26N No opposition filed

Effective date: 20160425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602009032308

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170201

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090730

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160730

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150722

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20181123

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530